• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
FDA Approves Yervoy (Ipilimumab), First Targeted Melanoma Therapy for Over a Decade - Product Image

FDA Approves Yervoy (Ipilimumab), First Targeted Melanoma Therapy for Over a Decade

  • Published: April 2011
  • Region: Global
  • 5 pages
  • GlobalData

FDA Approves Yervoy (Ipilimumab), First Targeted Melanoma Therapy for Over a Decade

Summary

Our report, “FDA Approves Yervoy (Ipilimumab), First Targeted Melanoma Therapy for Over a Decade” provides key update on the approval of Yervoy as the first targeted therapy for melanoma.

Scope

- Data and information on the FDA approval of Yervoy as the first targeted therapy for melanoma

Reasons to buy

- Develop understanding about the melanoma and how the approval of Yervoy will bring a paradigm shift in the treatment of melanoma.

1
1

2 Summary
3 Melanoma Overview
3.1 Disease Overview
3.2 Epidemiology
3.3 Diagnosis
4 Current Therapy Options
5 Unmet Need
6 Drivers and Barriers
6.1 Drivers
6.2 Barriers
7 Yervoy – New Second-Line Therapy for Advanced Metastatic Melanoma
7.1 020 Clinical Trial Details
7.2 Dosage and Pricing of Yervoy
8 Melanoma Market
9 Appendix
9.1 Methodology
9.1.1 Coverage
9.1.2 Secondary Research
9.1.3 Primary Research
9.1.4 Expert Panel Validation
9.2 Contact Us
9.3 Disclaimer

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos